Proteomics International Laboratories (ASX:PIQ)
ASX announcement history & article coverage
Transparent by design.
Announcments by Proteomics International Laboratories (ASX:PIQ) are listed here, whether we covered it or not. Where we've written an article, you'll see it linked directly. Where we haven't, the filing is still shown so nothing is hidden from view. If you think a particular announcement deserved editorial coverage and was overlooked, you can flag it for review and our team will take a look.
Ignite Investment Summit Presentation
PromarkerEndo Validation and Refinement Complete
Proteomics International validates Promarker®Endo blood test and targets FY27 Q3 commercial launch
Notice of AGM Date
Investor Presentation
PromarkerD and PromarkerEso Commercial Rollout Update
Proteomics International begins controlled PromarkerD and PromarkerEso rollout with Healius
Appendix 4E and Annual Report
Proteomics International reports FY2026 revenue growth, increased net loss, strategic reset, and new distribution deal
Appendix 4G and Corporate Governance Statement
Australian patent for PromarkerEndo
Proteomics International secures Australian patent acceptance for PromarkerEndo endometriosis diagnostic test
Change in substantial holding
Quarterly Activities/Appendix 4C Cash Flow Report
Proteomics International announces restructure, Healius distribution deal, US patent, and Q4 FY26 cash burn
Webinar Presentation - Healius distribution agreement
Proteomics signs national distribution deal with Healius
Proteomics International inks exclusive national distribution deal with Healius for Promarker® tests
